Nordic Nanovector Announces First Patient Dosed in Archer-1 Trial of Betalutin® Plus Rituximab in Follicular Lymphoma

OSLO, Norway, Nov. 2, 2018 /PRNewswire/ -- Nordic Nanovector ASA (OSE: NANO) announces that the first patient has been dosed in the Archer-1 trial investigating Betalutin® (177Lu-satetraxetan-lilotomab) in combination with rituximab (RTX) in second-line follicular lymphoma (2L FL)....

from PR Newswire: //https://ift.tt/2OkmfO8